| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Division of Rheumatology, University of Maryland, Baltimore
2 From the School of Medicine, University of Maryland, Baltimore
3 From the Johns Hopkins University, and the Division of Rheumatology, University of Maryland, Baltimore
4 From the Division of Pulmonology, University of Maryland, Baltimore
Eric L. Greidinger, MD, 720 Rutland Ave, Ross 1055, Johns Hopkins Division of Rheumatology, Baltimore, MD 21205
Study objectives: To determine whether African-American race is independently associated with lung disease in scleroderma.
Design: Retrospective review.
Setting: University medical center in Baltimore.
Patients: One hundred one patients with diffuse cutaneous scleroderma with available serum samples.
Measurements: Patients underwent lung function testing as part of their routine clinical care. Percent predicted values adjusted for race were calculated for FVC, single-breath carbon monoxide diffusing capacity (DCO), and FEV1. Serum samples were assayed for the presence of antibodies to topoisomerase I and RNA polymerase II.
Results: Scleroderma patients of African-American race had lower percent predicted values than white patients for FVC (p<0.002), DCO (p<0.0001), and FEV1 (p<0.0001). Antibodies to topoisomerase I but not antibodies to RNA polymerase II were also associated with lung function. African-American scleroderma patients were distinct from white patients in having younger age of onset and higher prevalence of antibodies to topoisomerase I. In multivariate analyses accounting for sex, age, smoking history, years of scleroderma symptoms, and RNA polymerase II antibody status, African-American race and topoisomerase I antibody status independently predicted lower lung function.
Conclusion: African-American race and antibodies to topoisomerase I are independent risk factors for scleroderma lung disease.
Key Words: autoantibodies • lung disease • race • scleroderma • topoisomerase I
Submitted on December 5, 1997
Accepted on February 5, 1998
This article has been cited by other articles:
|
|
 |
|
  W. D. DUAN-PORTER, L. CASCIOLA-ROSEN, and A. ROSEN Autoantigens: The Critical Partner in Initiating and Propagating Systemic Autoimmunity Ann. N.Y. Acad. Sci., December 1, 2005; 1062(1): 127 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Casciola-Rosen, K. Nagaraju, P. Plotz, K. Wang, S. Levine, E. Gabrielson, A. Corse, and A. Rosen Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy J. Exp. Med., February 22, 2005; 201(4): 591 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Le Guern, A. Mahr, L. Mouthon, D. Jeanneret, M. Carzon, and L. Guillevin Prevalence of systemic sclerosis in a French multi-ethnic county Rheumatology, September 1, 2004; 43(9): 1129 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rosen and L. Casciola-Rosen ALTERED AUTOANTIGEN STRUCTURE IN SJoGREN'S SYNDROME: IMPLICATIONS FOR THE PATHOGENESIS OF AUTOIMMUNE TISSUE DAMAGE Crit. Rev. Oral. Biol. Med., May 1, 2004; 15(3): 156 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Steen Predictors of end stage lung disease in systemic sclerosis Ann Rheum Dis, February 1, 2003; 62(2): 97 - 99. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
